US2011166178A1PendingUtilityA1

Methods for treating anemia using inhibitors of hypoxia-inducible factor (HIF) hydroxylase

60
Assignee: FIBROGEN INCPriority: Dec 6, 2001Filed: Feb 17, 2011Published: Jul 7, 2011
Est. expiryDec 6, 2021(expired)· nominal 20-yr term from priority
Inventors:Stephen J. KlausAl Y. LinThoams B. NeffQingjian WangVolkmar Guenzler-PukallMichael P. ArendLee A. FlippinAlex Melekhov
A61P 3/10A61P 9/00A61P 9/08A61P 9/10A61P 37/04A61P 9/04A61P 7/00A61P 9/12A61P 7/06A61P 39/00A61P 43/00A61P 37/00A61P 25/00A61P 35/00A61P 31/00A61P 25/28A61P 29/00A61P 25/14A61P 25/16A61P 25/08A61P 1/16A61P 17/02A61P 1/04A61P 13/12A61P 11/00A61K 31/4745A61K 31/44A61K 31/47A61K 31/4375C07K 14/505G01N 33/746A61K 38/1709A61K 31/4418A61K 31/63C07K 14/4702A61K 31/00A61K 31/17A61K 31/4738A61K 31/472A61K 31/496
60
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to methods for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo. Methods for treating, pretreating or preconditioning, or preventing erythropoietin-associated conditions are also included. Compounds for use in these methods are provided, as are methods of identifying such compounds.

Claims

exact text as granted — not AI-modified
1 . A method for treating anemia in a subject, the method comprising administering to the subject an effective amount of a compound that inhibits hypoxia-inducible factor (HIF) prolyl hydroxylase. 
     
     
         2 . The method of  claim 1 , wherein the subject is a subject having chronic kidney disease. 
     
     
         3 . The method of  claim 1 , wherein the compound is selected from the group consisting of a heterocyclic carboxamide, a phenanthroline, and a hydroxamate. 
     
     
         4 . The method of  claim 1 , wherein the compound is a heterocyclic carboxamide. 
     
     
         5 . The method of  claim 1 , wherein the subject is undergoing or is at risk for undergoing kidney dialysis. 
     
     
         6 . The method of  claim 1 , wherein the compound is delivered orally.

Join the waitlist — get patent alerts

Track US2011166178A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.